SGN NANOPHARMA INC
TAMPA, FLORIDA, FLORIDA

SGN NanoPharma Inc., established on April 25, 2017, is a Florida-based clinical-stage nanotherapeutics company with its headquarters located in Tampa, FL, at 3720 Spectrum Blvd, Suite 125. The company specializes in integrating proprietary nanotechnologies with structural biology to innovate superior medicinal solutions. SGN NanoPharma aims to be a leader in the global nanomedicine market and operates revenue-generating strategies focused on emerging markets such as India for MNP Technology-based products while concurrently conducting proof-of-concept clinical trials in low-cost geographies like India. The company's primary focus involves reformulating FDA-approved drugs that are sub-optimal, as well as developing novel therapies. A significant research and development endeavor of SGN NanoPharma is the creation of nano-cannabinoid candidate products aimed at transdermal delivery, enhancing bioavailability, and minimizing psychotropic effects. These efforts aim to offer safer alternatives for large dose therapies traditionally treated with potentially over-prescribed opiates. SGN NanoPharma engages in product marketing partnerships within India and other emerging markets as part of its revenue generation strategy from the outset. The organization has already taken steps towards this direction, emphasizing their commitment to generating revenue while expanding its scientific capabilities and market presence. Under the leadership of Navdeep S Jaikaria (P, C), Pranav Dr. Patel (Vice President), and Sunil Dr. Gupta (Director), SGN NanoPharma continues its innovative pursuits with a long-term vision for sustainable growth in the nanomedicine domain. More detailed information about the company can be accessed through their official website at sgnnanopharma.com, and they have maintained an active status with their last reinstatement event on October 11, 2021. The company is registered under Florida's corporate filing number P17000037685.